Patients should be encouraged to adopt healthy eating habits and engage in regular physical activity to maximize the benefits of these treatments and reduce the risk of regaining weight once the treatments are discontinued
Longer-duration studies suggest even greater potential: in a 68-week trial, patients lost up to 28.7% of body weight , exceeding outcomes typically seen with Zepbound
[1], [2], [3], [4] A 2021 retrospective study conducted at the Institute for Hormonal Balance in Orlando, Florida, that evaluated the use of BPC 157, alone or in combination with thymosin-beta-4 (TB4), indicates in its methodology that no human clinical trials evaluating the use of BPC 157 to help with knee pain have been published (see Table 1)
GLP-1 medication lingo and all the numbers that come with it can get confusing fast
Today, drugs like Ozempic (semaglutide), Wegovy, and Mounjaro (tirzepatide) are being prescribed and demanded for obesity, cardiometabolic risk, and even aesthetic weight loss